Linzess – pharmaceutical daily

June 19, 2019 Off

Ironwood, Allergan with positive topline data from LINZESS testing in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

– Phase IIIb study met all primary and secondary endpoints
with statistical significance and demonstrated that linaclotide improved
the overall abdominal symptoms of bloating, pain and discomfort in
adults with IBS-C –

January 26, 2017 Off

FDA OK’s Ironwood/Allergan’s constipation drug

By Dino Mustafić

Ironwood Pharmaceuticals and Allergan have won U.S. Food and Drug Administration’s (FDA) approval for 72 mcg dose of Linzess (linaclotide) for the treatment of chronic idiopathic constipation (CIC) in adult patients.

October 27, 2015 Off

Allergan Acquires Rights To Ironwood’s Constella

By Dino Mustafić

Allergan plc and Ironwood Pharmaceuticals, Inc. have announced that Allergan has acquired rights to Constella (linaclotide) in the European Union, Switzerland, Turkey and the Commonwealth of Independent States from Almirall, S.A. and has also reacquired rights to Linzess (linaclotide) in Mexico from Almirall.